Astrana Health Q2 2026 revenue rose 49% to $972.5 million, while net income attributable to shareholders more than doubled to $19.7 million.
Adjusted EBITDA (non-GAAP) climbed 43% to $68.9 million; adjusted EPS (non-GAAP, diluted) increased 45% to $0.80.
G&A improved 210 basis points to 5.6% of revenue, helped by continued deployment of proprietary AI-enabled tools.
Served about 1.5 million value-based patients, with about 1.2 million members in Care Partners; 81% of Q2 capitation revenue came from full-risk arrangements.
Kept FY 2026 revenue outlook at $3.8 billion-$4.1 billion, while raising adjusted EBITDA (non-GAAP) guidance to $255 million-$280 million.
ASTH•
